Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders
Romano Di Fabio, Annalisa Pellacani, Stefania Faedo, et al.
Bioorganic & Medicinal Chemistry Letters (2011) Vol. 21, Iss. 18, pp. 5562-5567
Closed Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases
Chunmei Wang, Qinqin Wang, Bingyuan Ji, et al.
Frontiers in Molecular Neuroscience (2018) Vol. 11
Open Access | Times Cited: 163
Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
Multiple roles for orexin/hypocretin in addiction
Stephen V. Mahler, Rachel J. Smith, David E. Moorman, et al.
Progress in brain research (2012), pp. 79-121
Open Access | Times Cited: 211
International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology
Anthony L. Gotter, Andrea L. Webber, Paul J. Coleman, et al.
Pharmacological Reviews (2012) Vol. 64, Iss. 3, pp. 389-420
Closed Access | Times Cited: 154
Role of Orexin-1 Receptor Mechanisms on Compulsive Food Consumption in a Model of Binge Eating in Female Rats
Laura Piccoli, Maria Vittoria Micioni Di Bonaventura, Carlo Cifani, et al.
Neuropsychopharmacology (2012) Vol. 37, Iss. 9, pp. 1999-2011
Open Access | Times Cited: 151
Discovery and development of orexin receptor antagonists as therapeutics for insomnia
Christopher J. Winrow, John J. Renger
British Journal of Pharmacology (2013) Vol. 171, Iss. 2, pp. 283-293
Open Access | Times Cited: 144
Dual Hypocretin Receptor Antagonism Is More Effective for Sleep Promotion than Antagonism of Either Receptor Alone
Stephen R. Morairty, Florent G. Revel, Pari Malherbe, et al.
PLoS ONE (2012) Vol. 7, Iss. 7, pp. e39131-e39131
Open Access | Times Cited: 117
Discovery of [(2R,5R)‐5‐{[(5‐Fluoropyridin‐2‐yl)oxy]methyl}‐2‐methylpiperidin‐1‐yl][5‐methyl‐2‐(pyrimidin‐2‐yl)phenyl]methanone (MK‐6096): A Dual Orexin Receptor Antagonist with Potent Sleep‐Promoting Properties
Paul J. Coleman, John D. Schreier, Christopher D. Cox, et al.
ChemMedChem (2012) Vol. 7, Iss. 3, pp. 415-424
Closed Access | Times Cited: 115
The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia
Paul J. Coleman, Anthony L. Gotter, W. Joseph Herring, et al.
The Annual Review of Pharmacology and Toxicology (2016) Vol. 57, Iss. 1, pp. 509-533
Closed Access | Times Cited: 113
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia
Anthony J. Roecker, Christopher D. Cox, Paul J. Coleman
Journal of Medicinal Chemistry (2015) Vol. 59, Iss. 2, pp. 504-530
Closed Access | Times Cited: 107
Tailor‐Made Amino Acids and Fluorinated Motifs as Prominent Traits in Modern Pharmaceuticals
Haibo Mei, Jianlin Han, S.W. White, et al.
Chemistry - A European Journal (2020) Vol. 26, Iss. 50, pp. 11349-11390
Closed Access | Times Cited: 107
Structure–Activity and Structure–Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1/NRF2) Protein–Protein Interaction
Tom D. Heightman, James F. Callahan, Elisabetta Chiarparin, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 9, pp. 4683-4702
Open Access | Times Cited: 76
Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia
Claudia Betschart, Samuel Hintermann, Dirk Behnke, et al.
Journal of Medicinal Chemistry (2013) Vol. 56, Iss. 19, pp. 7590-7607
Closed Access | Times Cited: 96
Orexin receptors as therapeutic drug targets
Anthony L. Gotter, Anthony J. Roecker, Richard Hargreaves, et al.
Progress in brain research (2012), pp. 163-188
Closed Access | Times Cited: 95
The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold
Anthony L. Gotter, Christopher J. Winrow, Joseph Brunner, et al.
BMC Neuroscience (2013) Vol. 14, Iss. 1
Open Access | Times Cited: 88
The brain orexin system and almorexant in fear-conditioned startle reactions in the rat
Michel A. Steiner, Hugues Lecourt, François Jenck
Psychopharmacology (2012) Vol. 223, Iss. 4, pp. 465-475
Closed Access | Times Cited: 78
Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism
Christine Dugovic, Jonathan Shelton, Sujin Yun, et al.
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 64
Discovery of 5′′‐Chloro‐N‐[(5,6‐dimethoxypyridin‐2‐yl)methyl]‐2,2′:5′,3′′‐terpyridine‐3′‐carboxamide (MK‐1064): A Selective Orexin 2 Receptor Antagonist (2‐SORA) for the Treatment of Insomnia
Anthony J. Roecker, Swati P. Mercer, John D. Schreier, et al.
ChemMedChem (2013) Vol. 9, Iss. 2, pp. 311-322
Closed Access | Times Cited: 62
Orexin/Hypocretin Based Pharmacotherapies for the Treatment of Addiction: DORA or SORA?
Shaun Yon‐Seng Khoo, Robyn M. Brown
CNS Drugs (2014) Vol. 28, Iss. 8, pp. 713-730
Open Access | Times Cited: 58
Orexin receptor antagonists as therapeutic agents for insomnia
Ana Clementina Equihua-Benítez, Alberto K. De la Herrán-Arita, René Drucker-Colı́n
Frontiers in Pharmacology (2013) Vol. 4
Open Access | Times Cited: 57
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
Free Ligand 1D NMR Conformational Signatures To Enhance Structure Based Drug Design of a Mcl-1 Inhibitor (AZD5991) and Other Synthetic Macrocycles
Amber Balazs, Rodrigo J. Carbajo, Nichola L. Davies, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 21, pp. 9418-9437
Open Access | Times Cited: 37
Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review
Aisha S. Shariq, Joshua D. Rosenblat, Asem Alageel, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018) Vol. 92, pp. 1-7
Closed Access | Times Cited: 36
Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs
Anil Kumar, Priyanka Chanana, Supriti Choudhary
Pharmacological Reports (2015) Vol. 68, Iss. 2, pp. 231-242
Closed Access | Times Cited: 35
Orexin OX2 Receptor Antagonists as Sleep Aids
Laura H. Jacobson, Sui Chen, Sanjida Mir, et al.
Current topics in behavioral neurosciences (2016), pp. 105-136
Open Access | Times Cited: 35
Page 1 - Next Page

Scroll to top